GlassScriptPhysician profile
Kristen Osterman Dutton
NPI 1669974515
$1,292.24
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $926 · 2024: $19.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.03 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $187.78 | 2022-2023 | Ninlaro |
| Seagen INC. | $159.46 | 2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $156.04 | 2023 | Calquence, Tagrisso |
| Incyte Corporation | $119.92 | 2023 | Jakafi |
| Daiichi Sankyo INC. | $108.13 | 2022-2023 | Enhertu |
| Genentech USA, INC. | $78.07 | 2022-2023 | Lunsumio, Polivy, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $64.07 | 2022-2023 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $60.06 | 2022-2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $58.53 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $53.02 | 2022-2023 | Somatuline Depot, Onivyde |
| Mirati Therapeutics, INC. | $31.47 | 2023 | Krazati |
| Celgene Corporation | $29.92 | 2023 | Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $28.36 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $24.45 | 2023 | Keytruda, Lynparza |
| Puma Biotechnology, INC. | $23.10 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $21.84 | 2023 | Panhematin |
| Boston Scientific Corporation | $19.27 | 2024 | Watchman Flx |
| Janssen Biotech, INC. | $19.06 | 2023 | Darzalex |
| Amgen INC. | $18.52 | 2023 | Lumakras |
| Lilly USA, LLC | $18.26 | 2023 | Retevmo, Jaypirca, Verzenio |
| Kyowa Kirin, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Dutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.